Hematopoietic growth factors for the treatment of aplastic anemia.
The use of hematopoietic growth factors, although well established for the management of chemotherapy-induced neutropenia, remains controversial for the treatment of aplastic anemia and inherited bone marrow failure syndromes. The most commonly used factors are granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and erythropoietin. Newer growth factors such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising results in the laboratory, and some have been used in clinical trials. This article reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited bone marrow failure, and discusses emerging concerns about long term toxicity of these factors.
Kumar
M
M
University of Texas Medical Branch at Galveston, Division of Pediatric Hematology/Oncology, Children's Hospital 77555-0361, USA.
Alter
B P
BP
D000741:Anemia, Aplastic / Q000188:drug therapy*; D001855:Bone Marrow Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D019089:Stem Cell Factor / Q000627:therapeutic use
D016298:Hematopoietic Cell Growth Factors; D019089:Stem Cell Factor; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor